1. Presentation Radboud Innovatie BootCamp 2015 Rob Lips
Nijmegen, 2 april 2015 GATT Technologies BV
GATT-Patch
Strategic or Financial investors?
GATT™ synthetic polyoxazoline (POX) platform
for surgical sealants and hemostats
GATT-Tape GATT- Patch

2. Agenda
From POX polymer to medical device business opportunity
14 April 2015 GATT Technologies BV 2
About GATT Technologies BV
The GATT-Patch product opportunity
The GATT-Patch industry opportunity
Strategy and financing

3. Johan Bender MSc Prof Harry v Goor
CEO, founder clinical partner
serial entrepreneur
About GATT
founded with a clinical ambition
14 April 2015 GATT Technologies BV 3
“The GATT technology platform will enable
medical device tapes and patches
with specific properties
optimized for the targeted clinical
application”
GATT Technologies BV :
founded in 2011 by Johan Bender
The unmet need :
anastomotic leakage: 3-15% with mortality 2-3%
The ambition : the GATT-Tape

4. About GATT
GATT-Tape : technology and successful proofs of concept
14 April, 2015 4
Approved PEG (Polyethyleneglycol ) sealant products
DuraSeal: CoSeal:
Successful Proofs of Concept
GATT-POX advantages over PEG
 strong adhesion
on wet tissue
water tight < 1-2 minutes
 GATT-Tape
production
Hot Melt Extrusion
POX poly(2-oxazoline)s has additional benefits:
 stronger adhesion
 better tuneable functionality
 non-brittle
PEG POX
+ End and side chains
+ Versatile synthesis
GATT Technologies BV

5. GATT-Tape
needed milestones and financing
14 April, 2015 GATT Technologies BV 5
GATT Technologies BV
Strategic
Partner
GATT Tape
Technical
Proof-of-Concept
X M€
GATT Tape
Pre-Clinical Studies
GATT Tape
Clinical Studies
Milestone CE
GATT Tape
Market intro
first Sales
0.X M€ X M€*
X M€ X M€
2015 2016 2018
* intended innovation loans
0.XM€
Financial Investors
Subsidies/Loans
Financial Investors ?

6. The large hemostatic and sealant market
trend to (semi) synthetic medical devices
14 April 2015 6
product
costs
adhesion strength
Hemostats Sealants
*time to hemostasis
medical
device
medicine
2005
Mechanical
hemostats
(1-10 min.)*
PEG
sealants
(<2 min.)*
GATT Technologies BV
Fibrin
powders
(<3 min.)*
Fibrin
gels
(<3 min.)*
Fibrin
spray sealants
(<5-10 min.)*
Fibrin
patches
(<3 min.)*
POX
GATT-Tape
(seal)

7. POX
GATT-Tape
(seal)
The product opportunity
clinical need for cost-effective, high-end hemostats
14 April 2015 7
product
costs
adhesion strength
Hemostats Sealants
*time to hemostasis
medical
device
medicine
Fibrin
patches
(<3 min.)*
2005
Mechanical
hemostats
(1-10 min.)*
2014 PEG
patches
(<2 min.)*
GATT Technologies BV
POX
GATT-Patch
(<1 min)*
GATT-Patch
> equal/better than
Baxter Hemopatch
2017

8. GATT-Patch
cost effective solution in expanding market segment
14 April, 2015 8
The opportunity: Baxter HemoPatch slipstream
BAXTER, recently introduced the Hemopatch
(a sealing hemostat):
 PEG-collagen based
 hemostatic medical device
 competitive pricing
 The GATT-Patch will have equal or better
characteristics than the BAXTER Hemopatch
 Especially on the faster time to hemostasis (< 1 min.)
and at least equal cost effectiveness.
 The GATT-Patch will be an attractive and profitable
completion of the product portfolio for most of the
major vendors
 expensive
 time to hemostatis 3 min.
The targeted GATT-Patch product
GATT Technologies BV

9. The industry opportunity
market shift to cost-effective, semi-synthetic medical devices
14 April 2015 9
product
costs
adhesion strength
Hemostats Sealants
*time to hemostasis
medical
device
medicine
Fibrin
patches
(<3 min.)*
PEG
patches
(<2 min.)*
POX
GATT-Patch
(<1 min)*
1
Mechanical
hemostats
(1-10 min.)*
2
GATT Technologies BV

10. The industry opportunity
targeted companies and confirmed interest
14 April 2015 10
1. Market players with expensive fibrin hemostats:
 a competitive high end “sealing” hemostat,
is a must for their sales channels
 the GATT POX technology will allow for a
complete competitive, cost-effective hemostat
portfolio
2. Market players with traditional mechanical
hemostats:
 enables shift of portfolio and expansion of
business to attractive high-end
GATT-Patch industry target Matrix:
GATT Technologies BV

11. * <= level as PEG
<< lower than Fibrin
The product opportunity
Profitable turnover
14 April, 2015 11
Value chain Turnover
The turnover potential for the GATT-Patch is
estimated at 50-150M€ at a targeted 10-20%
share in the high end market.
First sales will start at the end of 2017 with a
targeted sales turnover of 10-20M€ after 5 years
GATT Technologies BV

12. GATT-Patch BV
Strategy: separate legal entity with full business ownership
14 April, 2015 GATT Technologies BV 12
GATT Technologies BV
 IP
 POX technology platform
 product development
 supply of activated POX
Strategic Partner
 approved carrier + know-how
 production
 co-investment
 (distribution)
GATT Patch BV
 business and product
owner
 exclusive rights on
hemostat technology
large OEM partners distributors*
*independent and/or from strategic partner
product supply

13. GATT-Patch BV
deal construction for partnership GATT-Strategic Partner
14 April, 2015 GATT Technologies BV 13
GATT Technologies BV
Strategic Partner
GATT Patch BV
Technical
Proof-of-Concept
GATT-Tech 100%
X M€
GATT Patch BV
Pre-Clinical Studies
GATT-Tech 90%
Partner 10%
GATT Patch BV
Milestone CE
Clinical Studies
GATT-Tech 75%
Partner 25%
GATT Patch BV
Market intro
operational sales
endorsement studies
GATT-Tech 50%
Partner 50%
0.X M€ X M€*
X M€ X M€
2015-Q2 2016-Q2 2017
* intended innovation loans
0.XM€

14. GATT-Patch
Strategic or Financial investors?
GATT-Tape
Financial Investor
GATT- Patch
Strategic Investor
GATT Technologies BV Rob Lips r.lips@gatt-tech.com